Price movement over the last 24 hours
ADMA Biologics Inc vs Brookfield Infrastructure Partners LP — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Brookfield Infrastructure Partners LP trades at $37.26 (market cap $16.97B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 8× ADMA Biologics Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.94% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BIP | |
|---|---|---|
Market Cap | $2.13B | $16.97B |
Sector | Health | Industrials |
52-Week High | $20.38 | $40.08 |
52-Week Low | $7.60 | $29.81 |
Enterprise Value | $2.20B | $78.64B |
Dividend Yield | — | 4.94% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Brookfield Infrastructure Partners (BIP) trades at $37.31, up 0.81% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock carries a high P/E of 56.53 but attractive P/S of 0.71 and EV/EBITDA of 7.53. Recent earnings show volatility with two misses in the last three quarters, though Q2 2026 results are pending. The company maintains strong cash flow from operations of $6.0 billion and recently declared a $0.46 dividend.
BIP offers value through its discounted valuation and 5% yield, supported by inflation-linked contracts and infrastructure assets. However, risks include recent earnings misses, high debt levels, and sensitivity to interest rates. Analyst consensus is strongly bullish with a $45.50 price target, suggesting 22% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →